All News

In beginning the first phase 3 clinical trial to examine a vaccine candidate for the coronavirus disease 2019 (COVID-19), Moderna Inc announced that the Trump administration increased funding to expand the trial to 30,000 US participants; employers have considered and some have made it a requirement for employees to sign a waiver to not sue the organization if they are infected by COVID-19 or suffered any injury while working; study finds 1 flu shot can reduce the risk for Alzheimer disease by 17% and 1 pneumonia vaccine before age 75 can reduce the risk by 25%.

IQVIA, a health information technology and clinical research company, recently announced a new collaboration with JDRF, the world’s largest nonprofit funder of type 1 diabetes (T1D) research. Together, the companies plan to develop a real-world research platform to facilitate evidence generation for T1D via non-identified patient-level data and analytics.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

This week, the top managed care news included states suing the Trump administration over an HHS rule on nondiscrimination; experimental vaccines show promise against COVID-19 in healthy subjects; diagnostic delays from COVID-19 may increase cancer-related deaths.

The health burden of comorbid chronic obstructive pulmonary disease (COPD) and asthma is known to be greater than when either condition exists on its own. An upcoming study shows that COPD is linked with greater all-cause mortality and greater risk of mortality in patients with coexisting asthma who also had long-term use of corticosteroids.

New CDC data outline the prevalence of 5 common underlying health conditions that exacerbate coronavirus disease 2019 (COVID-19) symptoms; the FDA announced information regarding naloxone must be included on labels for opioids and opioid use disorder medications; despite a district judge's ruling nearly a month ago, hundreds of migrant detainees are being held in detention centers in states where COVID-19 cases are surging.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo